FY2026 Runaway Homeless Youth Training, Technical Assistance, and Capacity Building Center (RHYTTAC)
- Response deadline
- Aug 14, 2026 Closed
- Date posted
- Jul 15, 2026
- Source
- Open notice
Description
The Runaway and Homeless Youth Training, Technical Assistance, and Capacity Building Center (RHYTTAC) provides direct training and technical assistance to existing RHY award recipients and subrecipients to enhance their efforts to successfully implement FYSB-funded projects. FYSB expects to award one cooperative agreement to strengthen and build the capacity of runaway and homeless youth and other youth-serving professionals and service providers across the nation by:Developing relevant and interactive training products for in-person and virtual adaptation.Disseminating evidenced-based, evidence-informed, and best practices related to issues impacting youth who have runaway from home, youth and young adults experiencing homelessness, and youth and young adults at risk of becoming homeless.Providing targeted technical assistance to RHY award recipients and youth-serving organizations to address current and potential needs.Leading coordination activities among RHY award recipients and other RHY funded partner organizations.
Classifications
- NAICS93.623
Documents (1)
- HHS-2026-ACF-ACYF-CY-0159_Announcement.pdfapplication/pdf385 KBNot yet available
Contacts
Similar contracts
- ​​FY 2026 Basic Center Program​Due Aug 17, 2026
- National Communication System for Runaway and Homeless Youth ProgramDue Aug 19, 2026
- Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)Due Mar 5, 2029
- NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)Due May 26, 2027
- Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)Due Jan 10, 2028
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Due Feb 8, 2028